Actively Recruiting
Guanfacine Extended-release for Adolescents With Cannabis Use
Led by Orygen · Updated on 2025-07-31
100
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
O
Orygen
Lead Sponsor
Y
Youth Support and Advocacy Service
Collaborating Sponsor
AI-Summary
What this Trial Is About
A randomized controlled trial to assess the efficacy of extended-release guanfacine to reduce cannabis use frequency in young people with cannabis use disorder following a period of monitored abstinence.
CONDITIONS
Official Title
Guanfacine Extended-release for Adolescents With Cannabis Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 12 to 25 years of age at consent
- Seeking treatment for cannabis use
- Diagnosed with mild, moderate, or severe Cannabis Use Disorder according to DSM-5
- Self-reported cannabis use at least 5 days per week during the 28 days before screening with a THC positive urine test on screening day
- Able to provide informed consent with adequate IQ and English fluency; participants under 18 must have both their own and their parent or guardian's consent
You will not qualify if you...
- Moderate or severe substance use disorder other than cannabis or nicotine
- Unstable medical, psychiatric, or neurological conditions or other medical issues that contraindicate participation
- Diagnosis of psychotic or bipolar illness
- Acute suicidality as assessed by a clinician
- Current prescription of antipsychotics, benzodiazepines, sedatives, or ADHD medications; antidepressants allowed only if stable dose for over 2 weeks
- History of heart disease or cardiac risk factors such as arrhythmias
- Abnormal liver or thyroid function based on significant blood test findings
- Pregnancy, breastfeeding, or sexually active without effective contraception
- Planning to enter residential rehabilitation after treatment in the youth residential withdrawal facility
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Orygen
Parkville, Victoria, Australia, 3052
Actively Recruiting
Research Team
G
Gillinder Bedi, DPsych
CONTACT
E
Emily A Karanges, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here